MOA

EVAP and Assembrix Announce Strategic Partnership to enhance UAE's Additive Manufacturing eco-system

Retrieved on: 
Monday, October 2, 2023
Partnership, MOA, VMS, Defense, GCC, ABU, EVAP, TEL, Aerospace, AM, Emirati, Software, Food delivery, Drug

This strategic partnership is steered by the vision of establishing a global software bridge between multi-nationals already using additive manufacturing (AM) and the Emirati advanced manufacturing eco-system.

Key Points: 
  • This strategic partnership is steered by the vision of establishing a global software bridge between multi-nationals already using additive manufacturing (AM) and the Emirati advanced manufacturing eco-system.
  • "We are pleased to partner with EVAP Investment and excited to be part of huge opportunities of the additive manufacturing market in the UAE.
  • Our partnership will achieve a new milestone of innovation and progress in the UAE and GCC regions' additive manufacturing landscape.
  • This will be achieved by utilizing Assembrix' Virtual Manufacturing Space platform ("VMS") product for remote control additive manufacturing in conjunction with local smart factories.

EVAP and Assembrix Announce Strategic Partnership to enhance UAE's Additive Manufacturing eco-system

Retrieved on: 
Monday, October 2, 2023
Partnership, MOA, VMS, Defense, GCC, ABU, EVAP, TEL, Aerospace, AM, Emirati, Software, Food delivery, Drug

This strategic partnership is steered by the vision of establishing a global software bridge between multi-nationals already using additive manufacturing (AM) and the Emirati advanced manufacturing eco-system.

Key Points: 
  • This strategic partnership is steered by the vision of establishing a global software bridge between multi-nationals already using additive manufacturing (AM) and the Emirati advanced manufacturing eco-system.
  • "We are pleased to partner with EVAP Investment and excited to be part of huge opportunities of the additive manufacturing market in the UAE.
  • Our partnership will achieve a new milestone of innovation and progress in the UAE and GCC regions' additive manufacturing landscape.
  • This will be achieved by utilizing Assembrix' Virtual Manufacturing Space platform ("VMS") product for remote control additive manufacturing in conjunction with local smart factories.

Certis Oncology Solutions Highlights AI & Machine Learning With Advanced Preclinical Cancer Models for Improved Clinical Translation in Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, September 28, 2023
Biology, Artificial intelligence, Cancer, AI, CDT, Intelligence, MOA, Biochemistry, Biomarker, Machine learning, Doctor of Philosophy, Medical imaging

TORONTO, Sept. 28, 2023 /PRNewswire-PRWeb/ -- In recent years, the biopharmaceutical industry has become keenly interested in adopting artificial intelligence (AI)-driven platforms. These AI and machine learning platforms can be used for streamlining R&D efforts, reducing discovery timelines and costs, and improving efficiency. At the same time, the demand for predictive and robust preclinical cancer models to minimize translational failures in oncology is at an all-time high.

Key Points: 
  • TORONTO, Sept. 28, 2023 /PRNewswire-PRWeb/ -- In recent years, the biopharmaceutical industry has become keenly interested in adopting artificial intelligence (AI)-driven platforms.
  • These AI and machine learning platforms can be used for streamlining R&D efforts, reducing discovery timelines and costs, and improving efficiency.
  • At the same time, the demand for predictive and robust preclinical cancer models to minimize translational failures in oncology is at an all-time high.
  • The demand for predictive and robust preclinical cancer models to minimize translational failures in oncology is at an all-time high.

Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting

Retrieved on: 
Tuesday, September 26, 2023
Volunteering, Obesity, Human body weight, MOA, Therapy, T1D, Weight loss, Clinical trial, Type 2 diabetes, Pharmacokinetics, PYY, DSM-IV codes, Patient, CEST, Overweight, GIP, European Association for the Study of Diabetes, T2D, Diabetes, Medical imaging, Birth control, Communications satellite, Vaccine, Philosopher's stone

BERKELEY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to delivering life-changing therapeutics for people with metabolic diseases, today announced two oral presentations to take place at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany. Details regarding the clinical data presentations are as follows:

Key Points: 
  • Carmot expects to initiate additional Phase 2 trials for obesity and T2D.
  • Carmot has recently initiated an additional Phase 1 MOA study in adults with overweight/obesity with type 1 diabetes (T1D) and expects to initiate a Phase 2 proof-of-concept clinical trial in participants with overweight/obesity with T1D.
  • CT-996 (once-daily oral, small molecule GLP-1 receptor agonist) is currently in a multi-arm, multi-cohort Phase 1 clinical trial in adults with overweight/obesity as well as in patients with T2D.
  • A long-acting peptide tyrosine-tyrosine (PYY) analogue, which is in preclinical development.

Enveda Biosciences Named One of Biotech’s Most Promising Startups by Endpoints News

Retrieved on: 
Thursday, September 21, 2023
Start-Up, Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Research, Software, Artificial Intelligence, Science, Clinical Trials, Drug discovery, Inflammatory bowel disease, Surrogate endpoint, MOA, Atopic dermatitis, Life, Patient, Inflammation, News, Machine learning, Medical imaging

Enveda Biosciences, a biotechnology company discovering new medicines from the natural world, has been chosen by the Endpoints News editorial team as one of the most promising biotech startups in this year’s Endpoints 11 annual special report.

Key Points: 
  • Enveda Biosciences, a biotechnology company discovering new medicines from the natural world, has been chosen by the Endpoints News editorial team as one of the most promising biotech startups in this year’s Endpoints 11 annual special report.
  • Enveda has built a first of its kind platform for industrial scale natural product drug discovery.
  • The second, addressing atopic dermatitis, inhibits neutrophil migration through a unique MOA, blocking multiple chemoattractant pathways with a single molecule.
  • Our platform is super-powering our ability to find and utilize these solutions, and we’re grateful to the Endpoints team for highlighting the importance of this work,” says Colluru.

Sarcomatrix Therapeutics Corp.’s Exclusive Research Partner Strykagen Awarded SBIR Phase 2 Grant from the National Institutes of Health (NIH) to Advance Small Molecules Promoting Muscle Regeneration

Retrieved on: 
Wednesday, September 20, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, MOA, Therapy, Office of the Director of Civil Aviation, SBIR, Muscular dystrophy, Small Business Innovation Research, Research, Bangladesh Technical Education Board, Sarcopenia, Investigational New Drug, Cachexia, Integrin, Corp, IND, NIH, Pharmaceutical industry

“We are grateful for the Phase 2 SBIR grant from the NIH for S-969, a continuation of our initial grant supporting the advancement of S-969 through early pre-clinical studies,” said Ryan Wuebbles, Ph.D., Chief Science Officer, Strykagen.

Key Points: 
  • “We are grateful for the Phase 2 SBIR grant from the NIH for S-969, a continuation of our initial grant supporting the advancement of S-969 through early pre-clinical studies,” said Ryan Wuebbles, Ph.D., Chief Science Officer, Strykagen.
  • “This grant allows us to evaluate the efficacy of S-969 in standard dose ranging models and complete IND enabling actions before entering the clinic.”
    Research reported in this publication was supported by the Office of The Director, National Institutes of Health of the National Institutes of Health under Award Number 2R44OD030543-04.
  • The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.
  • This press release contains forward-looking statements, which, aside from historical facts, include future projections subject to significant risks, especially concerning Sarcomatrix’ s development programs.

Metroland Media betrays workers and communities with local news cuts

Retrieved on: 
Friday, September 15, 2023
Heart, Learning, Private sector, Employment, MOA, Democracy, Metroland Media Group, Unifor, Unifor National Council 4000, Social justice, Local, Heel, Metroland, News, Social media, Health insurance, Nordstar

Devastating for these media workers.

Key Points: 
  • Devastating for these media workers.
  • Devastating for the communities who depend on that local news and devastating for the fabric of our democracy," says Lana Payne, Unifor National President.
  • Metroland Media provided no notice of the layoffs to the local union.
  • Unifor is Canada's largest union in the private sector and represents 315,000 workers in every major area of the economy.

Celcuity to Host Virtual Science Day for Investors

Retrieved on: 
Thursday, September 7, 2023
University, MOA, Senior, Hematology, University of Washington Department of Global Health, Phase 3, Breast, Patient, Breast cancer, Division, CELC, Maghreb Virtual Science Library, Webcast, Institut Gustave Roussy, Oncology, Fred Hutchinson Cancer Research Center, UCLA, Gustav, Disease, Prostate cancer, Pharmaceutical industry, Medical imaging

ET on September 21, 2023

Key Points: 
  • ET on September 21, 2023
    MINNEAPOLIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will host a Virtual Science Day for analysts and investors from 10:00 a.m. – 12:00 p.m.
  • In early 2024, Celcuity expects to initiate the Phase 1b/2 CELC-G-201 trial of gedatolisib in combination with the androgen receptor inhibitor Nubeqa® (darolutamide) in metastatic castration resistant prostate cancer.
  • Celcuity’s Virtual Science Day for analysts and investors will take place on Thursday, September 21, 2023, from 10:00 a.m. to 12:00 p.m.
  • A replay of the webcast will be available on the “Events & Presentations” section of Celcuity’s website following the event.

IBN Coverage Initiated for Longeveron Inc.

Retrieved on: 
Thursday, September 7, 2023
Human, Hypoplastic left heart syndrome, MOA, Bone marrow, Ageing, Lead, Research, Inflammation, Life expectancy, Medicine, Longevity, Health, HLHS, Social media, IBN, Conditional sentence, Pharmaceutical industry, Dietary supplement

The Company is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty.

Key Points: 
  • The Company is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty.
  • Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors.
  • As part of the Client Partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets , various newsletters , social media channels , wire services via InvestorWire , blogs and other outreach tools to generate greater awareness for Longeveron .
  • IBN is uniquely positioned to provide Longeveron the solutions needed to reach a wide audience of investors, journalists and the general public.

Mall of America® Partners with Axis Communications to Enhance Safety and Visitor Experience with Modern Surveillance and Security Upgrades

Retrieved on: 
Thursday, September 7, 2023
Networks, Other Retail, Hardware, Department Stores, Specialty, Technology, Commercial Building & Real Estate, Construction & Property, Security, Retail, Building Systems, Other Technology, MOA, Axis Communications, Classification, Mall of America, Office, Multimedia, PTZ, Restaurant, Bloomington, Pan–tilt–zoom camera, M50, AEC, AXIS, Safety, Casino, Telescopic sight, Axis, Mall

Mall of America® (MOA) and Axis Communications today announced new upgrades to the comprehensive surveillance and security system deployed by the retail giant and popular tourist destination.

Key Points: 
  • Mall of America® (MOA) and Axis Communications today announced new upgrades to the comprehensive surveillance and security system deployed by the retail giant and popular tourist destination.
  • These upgrades include intelligent Axis cameras intended to augment the safety personnel who help maintain a safe, carefree environment for the mall’s many visitors and staff members.
  • View the full release here: https://www.businesswire.com/news/home/20230907956263/en/
    Mall of America® upgrades surveillance and security with Axis panoramic, pan/tilt/zoom (PTZ), dome, and body worn cameras.
  • “We are proud of the role Axis has played in helping Mall of America enhance its safety, security, and overall customer experience,” said Karl Radke, Midwest Business Area Director at Axis.